Desitin Arzneimittel Gmbh
🇳🇴Norway
- Country
- 🇳🇴Norway
- Ownership
- Private
- Established
- 1919-01-01
- Employees
- 251
- Market Cap
- -
- Website
- http://www.desitin.de
Bioavailability of Orfiril Long 500 mg Prolonged-Release Minitablets and Ergenyl Chrono 500 mg Prolonged-Release Tablets
Phase 1
Completed
- Conditions
- Multiple Drug Use
- Interventions
- Drug: Sodium valproate 500 MGDrug: Valproic Acid 500 MG
- First Posted Date
- 2024-01-19
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Desitin Arzneimittel GmbH
- Target Recruit Count
- 22
- Registration Number
- NCT06214130
- Locations
- 🇨🇦
Biopharma Services INC, Toronto, Canada
Bioavailability and Food Effect of Sodium Valproate Minitablets in Healthy Subjects.
- First Posted Date
- 2024-01-18
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- Desitin Arzneimittel GmbH
- Target Recruit Count
- 28
- Registration Number
- NCT06211283
- Locations
- 🇨🇦
Biopharma Services INC, Toronto, Canada
Single-dose, Two-way Crossover Bioequivalence of Lamotrigine in Healthy Male Volunteers Under Fasting Conditions
- First Posted Date
- 2024-01-10
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- Desitin Arzneimittel GmbH
- Target Recruit Count
- 24
- Registration Number
- NCT06199791
- Locations
- 🇨🇦
Biopharma Services INC, Toronto, Canada
Efficacy, Safety and Tolerability of Sulthiame in Patients With Obstructive Sleep Apnea (OSA)
- First Posted Date
- 2022-02-11
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- Desitin Arzneimittel GmbH
- Target Recruit Count
- 298
- Registration Number
- NCT05236842
- Locations
- 🇧🇪
Pneumocare SRL, Namur, Belgium
Pharmacokinetic Study With Levodopa-carbidopa Fixed-dose Products in Healthy Subjects After Oral Administration
Phase 1
Completed
- Conditions
- Fasted State
- Interventions
- First Posted Date
- 2014-04-17
- Last Posted Date
- 2014-04-17
- Lead Sponsor
- Desitin Arzneimittel GmbH
- Target Recruit Count
- 12
- Registration Number
- NCT02116465
- Locations
- 🇧🇬
Department of Clinical Pharmacology, Sofia, Bulgaria
PIRLONG-PD Safety and Efficacy of Piribedil in Parkinson's Disease During Long Term Therapy
- First Posted Date
- 2012-01-27
- Last Posted Date
- 2016-01-29
- Lead Sponsor
- Desitin Arzneimittel GmbH
- Target Recruit Count
- 908
- Registration Number
- NCT01519856
- Locations
- 🇩🇪
Dr. Erich Scholz, Boeblingen, Baden-Wuertemberg, Germany
ESOXC-ER Efficacy and Safety of an Extended Release (ER) Formulation of Oxcarbazepine (Apydan Extent) in Epileptic Patients
Completed
- Conditions
- Epilepsy
- First Posted Date
- 2010-03-15
- Last Posted Date
- 2013-03-01
- Lead Sponsor
- Desitin Arzneimittel GmbH
- Target Recruit Count
- 225
- Registration Number
- NCT01086501
- Locations
- 🇩🇪
Dr. Stephan Arnold, Munich, Bavaria, Germany
Influence of Piribedil (Clarium®) on Vigilance and Cognitive Function in Patients With Parkinson's Disease Compared to Other Non-Ergot Dopamine Agonists
Phase 3
Completed
- Conditions
- Idiopathic Parkinson's Disease
- Interventions
- First Posted Date
- 2009-11-04
- Last Posted Date
- 2012-05-24
- Lead Sponsor
- Desitin Arzneimittel GmbH
- Target Recruit Count
- 80
- Registration Number
- NCT01007864
Valproate Sustained Release Minitablets (Orfiril(R) Long) Once Daily in the Evening
- First Posted Date
- 2009-03-27
- Last Posted Date
- 2009-05-20
- Lead Sponsor
- Desitin Arzneimittel GmbH
- Target Recruit Count
- 82
- Registration Number
- NCT00870688
SEDPARK2: Post Marketing Surveillance to Observe Safety and Efficacy of Piribedil in Parkinson's Disease (PIR-002/K)
- First Posted Date
- 2008-08-04
- Last Posted Date
- 2009-02-25
- Lead Sponsor
- Desitin Arzneimittel GmbH
- Target Recruit Count
- 750
- Registration Number
- NCT00727727
- Locations
- 🇩🇪
Medical Practice for Neurology, Wedel, Germany
© Copyright 2025. All Rights Reserved by MedPath